2017 International Symposium on RNA Nanotechnology Based Targeted Therapy
Speakers of this symposium included Dr. Peixuan Guo, endowed chair professor of The Ohio State University, USA; Jun Lu, president of Chinese Geriatrics Society; Haibo Hu, CEO of Nanobio Delivery Pharmaceutical Co., Ltd; and many of the world's top experts in both basic and clinical medical/pharmaceutical fields from universities, hospitals and research institutions.
RNA molecules have become increasingly attractive because of the amazing diversity of their structures and functions. RNA can be manipulated with ease, much like DNA, yet it also has tremendous structural flexibility and functional diversity similar to some proteins. Thus, RNA as a nanomaterial has the advantages of both protein and DNA worlds. The unique properties in terms of free energy, folding, non-canonical base-pairing, base-stacking, and distinctive in vivo attributes have propelled RNA nanotechnology as its own technological discipline. By definition, RNA nanotechnology allows the integration of multiple functional RNA modules into one nanoparticles, of which the scaffolds, ligands, therapeutics, and regulators can be composed all of RNA. The field of RNA nanotechnology was initiated by Dr. Peixuan Guo in 1998, when he demonstrated the concept of building RNA nanoparticles using reengineered RNA fragments (published in Molecular Cell; featured in Cell). Since then RNA nanotechnology has grown into a mature field composed of several subfields covered by many disciplines.
Nanobio Delivery Pharmaceutical Co., Ltd is currently the only one in the world to supply high-quality and large-scale RNA nanoparticles as a commercial product for pre-clinical usage and eventual clinical trials. The company has an experienced team of scientists to actively work with researchers and custom-design RNA nanoparticles for target applications. Recently, Nanobio Delivery has actively worked with The Ohio State University to setup a Center for RNA Nanotechnology and Nanomedicine and is making great efforts to collaborate with the top research teams to efficiently coordinate a multidisciplinary effort to transition RNA nanotechnology from the bench to the clinic.
Further reading: Jasinski D, Haque F, Binzel DW, Guo P. Advancement of the Emerging Field of RNA Nanotechnology. ACS Nano. 2017; 11(2):1142-1164 (Link).